The influence of aluminium hydroxide on the bioavailability of feprazone. Single dose study.
The influence of aluminium hydroxide (given as a suspension, Aludrox) on the oral bioavailability of feprazone was tested. The degree and speed of absorption of feprazone from capsules (400 mg feprazone as a single dose; 8 volunteers) was investigated by determining plasma levels of feprazone and one of its metabolites using an HPLC method. No statistically significant change in feprazone kinetics caused by the antacid was evident. Cmax (means +/- SEM) decreased from 40.6 +/- 2.9 to 36.25 +/- 1.4 micrograms/ml; the mean area under the plasma level time curve was somewhat higher after additional administration of aluminium hydroxide (n. s.).
D000328:Adult; D000536:Aluminum Hydroxide / Q000494:pharmacology*; D001682:Biological Availability; D001711:Biotransformation; D005260:Female; D011298:Feprazone / Q000378:metabolism*; D006207:Half-Life; D006801:Humans; D008297:Male; D010653:Phenylbutazone / Q000031:analogs & derivatives*
D000536:Aluminum Hydroxide; D011298:Feprazone; D010653:Phenylbutazone